Follow
Guillermo Prado Vázquez
Guillermo Prado Vázquez
investigador predoctoral, Hospital Universitario La Paz
Verified email at estudiante.uam.es
Title
Cited by
Cited by
Year
A novel approach to triple-negative breast cancer molecular classification reveals a luminal immune-positive subgroup with good prognoses
G Prado-Vázquez, A Gámez-Pozo, L Trilla-Fuertes, JM Arevalillo, ...
Scientific reports 9 (1), 1538, 2019
732019
Functional proteomics outlines the complexity of breast cancer molecular subtypes
A Gámez-Pozo, L Trilla-Fuertes, J Berges-Soria, N Selevsek, ...
Scientific Reports 7 (1), 10100, 2017
532017
Prediction of adjuvant chemotherapy response in triple negative breast cancer with discovery and targeted proteomics
A Gámez-Pozo, L Trilla-Fuertes, G Prado-Vázquez, C Chiva, ...
PLoS One 12 (6), e0178296, 2017
302017
Molecular characterization of breast cancer cell response to metabolic drugs
L Trilla-Fuertes, A Gámez-Pozo, JM Arevalillo, M Díaz-Almirón, ...
Oncotarget 9 (11), 9645, 2018
222018
Urothelial cancer proteomics provides both prognostic and functional information
G de Velasco, L Trilla-Fuertes, A Gamez-Pozo, M Urbanowicz, ...
Scientific Reports 7 (1), 15819, 2017
212017
Biological molecular layer classification of muscle-invasive bladder cancer opens new treatment opportunities
L Trilla-Fuertes, A Gámez-Pozo, G Prado-Vázquez, A Zapater-Moros, ...
BMC cancer 19, 1-9, 2019
192019
Computational models applied to metabolomics data hints at the relevance of glutamine metabolism in breast cancer
L Trilla-Fuertes, A Gámez-Pozo, E López-Camacho, G Prado-Vázquez, ...
BMC cancer 20, 1-11, 2020
142020
Melanoma proteomics suggests functional differences related to mutational status
L Trilla-Fuertes, A Gámez-Pozo, G Prado-Vázquez, A Zapater-Moros, ...
Scientific reports 9 (1), 7217, 2019
122019
Comprehensive characterization of the mutational landscape in localized anal squamous cell carcinoma
L Trilla-Fuertes, I Ghanem, J Maurel, G Laura, M Mendiola, C Peńa, ...
Translational Oncology 13 (7), 100778, 2020
112020
Probabilistic graphical models relate immune status with response to neoadjuvant chemotherapy in breast cancer
A Zapater-Moros, A Gámez-Pozo, G Prado-Vázquez, L Trilla-Fuertes, ...
Oncotarget 9 (45), 27586, 2018
102018
Proteomics characterisation of central nervous system metastasis biomarkers in triple negative breast cancer
K Rojas, L Trilla-Fuertes, A Gámez-Pozo, C Chiva, J Sepúlveda, L Manso, ...
ecancermedicalscience 13, 2019
92019
miRNA profiling in renal carcinoma suggest the existence of a group of pro-angionenic tumors in localized clear cell renal carcinoma
L Trilla-Fuertes, N Miranda, D Castellano, R López-Vacas, ...
PloS one 15 (2), e0229075, 2020
72020
Bayesian networks established functional differences between breast cancer subtypes
L Trilla-Fuertes, A Gámez-Pozo, JM Arevalillo, R López-Vacas, ...
PloS one 15 (6), e0234752, 2020
62020
Computational metabolism modeling predicts risk of distant relapse-free survival in breast cancer patients
L Trilla-Fuertes, A Gámez-Pozo, M Díaz-Almirón, G Prado-Vázquez, ...
Future Oncology 15 (30), 3483-3490, 2019
52019
Genetic profile and functional proteomics of anal squamous cell carcinoma: Proposal for a molecular classification
L Trilla-Fuertes, I Ghanem, A Gamez-Pozo, J Maurel, G Laura, ...
Molecular & Cellular Proteomics 19 (4), 690-700, 2020
42020
A novel molecular analysis approach in colorectal cancer suggests new treatment opportunities
E López-Camacho, G Prado-Vázquez, D Martínez-Pérez, ...
Cancers 15 (4), 1104, 2023
32023
Molecular characterization of triple negative breast cancer formaldehyde‐fixed paraffin‐embedded samples by data‐independent acquisition proteomics
S García‐Adrián, L Trilla‐Fuertes, A Gámez‐Pozo, C Chiva, ...
Proteomics 22 (3), 2100110, 2022
32022
Abstract P5-12-14: A pilot study of metabolomics biomarkers in breast cancer tumors treated with neoadjuvant therapy
P Zamora, L Trilla-Fuertes, A Zapater-Moros, A Gámez-Pozo, ...
Cancer Research 79 (4_Supplement), P5-12-14-P5-12-14, 2019
12019
Tumor-infiltrating lymphocytes expression in stage IIIc/IV of high-grade serous ovarian cancer: Variation with neoadjuvant chemotherapy and prognostic value
K Rojas, G Prado-Vazquez, C Barcena, L Trilla-Fuertes, A Gamez-Pozo, ...
Oncogen Journal 2 (2), 8, 2019
12019
Melanoma proteomics unravels major differences related to mutational status
L Trilla-Fuertes, A Gámez-Pozo, G Prado-Vázquez, A Zapater-Moros, ...
bioRxiv, 198358, 2017
12017
The system can't perform the operation now. Try again later.
Articles 1–20